168 related articles for article (PubMed ID: 26000378)
1. Liposomes versus lipid nanoparticles: comparative study of lipid-based systems as oryzalin carriers for the treatment of leishmaniasis.
Lopes RM; Gaspar MM; Pereira J; Eleutério CV; Carvalheiro M; Almeida AJ; Cruz ME
J Biomed Nanotechnol; 2014 Dec; 10(12):3647-57. PubMed ID: 26000378
[TBL] [Abstract][Full Text] [Related]
2. Formulation of oryzalin (ORZ) liposomes: in vitro studies and in vivo fate.
Lopes RM; Corvo ML; Eleutério CV; Carvalheiro MC; Scoulica E; Cruz ME
Eur J Pharm Biopharm; 2012 Oct; 82(2):281-90. PubMed ID: 22771930
[TBL] [Abstract][Full Text] [Related]
3. Lipid nanoparticles containing oryzalin for the treatment of leishmaniasis.
Lopes R; Eleutério CV; Gonçalves LM; Cruz ME; Almeida AJ
Eur J Pharm Sci; 2012 Mar; 45(4):442-50. PubMed ID: 21983568
[TBL] [Abstract][Full Text] [Related]
4. Lipid-based nanoformulations of trifluralin analogs in the management of Leishmania infantum infections.
Lopes RM; Pereira J; Esteves MA; Gaspar MM; Carvalheiro M; Eleutério CV; Gonçalves L; Jiménez-Ruiz A; Almeida AJ; Cruz ME
Nanomedicine (Lond); 2016 Jan; 11(2):153-70. PubMed ID: 26651236
[TBL] [Abstract][Full Text] [Related]
5. Hemisynthetic trifluralin analogues incorporated in liposomes for the treatment of leishmanial infections.
Carvalheiro M; Esteves MA; Santos-Mateus D; Lopes RM; Rodrigues MA; Eleutério CV; Scoulica E; Santos-Gomes G; Cruz ME
Eur J Pharm Biopharm; 2015 Jun; 93():346-52. PubMed ID: 25936854
[TBL] [Abstract][Full Text] [Related]
6. Carvacrol loaded nanostructured lipid carriers as a promising parenteral formulation for leishmaniasis treatment.
Galvão JG; Santos RL; Silva ARST; Santos JS; Costa AMB; Chandasana H; Andrade-Neto VV; Torres-Santos EC; Lira AAM; Dolabella S; Scher R; Kima PE; Derendorf H; Nunes RS
Eur J Pharm Sci; 2020 Jul; 150():105335. PubMed ID: 32272211
[TBL] [Abstract][Full Text] [Related]
7. Drug delivery: lessons to be learnt from Leishmania studies.
Shaw CD; Carter KC
Nanomedicine (Lond); 2014 Jul; 9(10):1531-44. PubMed ID: 25253500
[TBL] [Abstract][Full Text] [Related]
8. Orally Bioavailable and Effective Buparvaquone Lipid-Based Nanomedicines for Visceral Leishmaniasis.
Smith L; Serrano DR; Mauger M; Bolás-Fernández F; Dea-Ayuela MA; Lalatsa A
Mol Pharm; 2018 Jul; 15(7):2570-2583. PubMed ID: 29762040
[TBL] [Abstract][Full Text] [Related]
9. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.
Borborema SE; Schwendener RA; Osso JA; de Andrade HF; do Nascimento N
Int J Antimicrob Agents; 2011 Oct; 38(4):341-7. PubMed ID: 21783345
[TBL] [Abstract][Full Text] [Related]
10. Development and evaluation of a cedrol-loaded nanostructured lipid carrier system for in vitro and in vivo susceptibilities of wild and drug resistant Leishmania donovani amastigotes.
Kar N; Chakraborty S; De AK; Ghosh S; Bera T
Eur J Pharm Sci; 2017 Jun; 104():196-211. PubMed ID: 28400285
[TBL] [Abstract][Full Text] [Related]
11. Development and performance evaluation of alginate-capped amphotericin B lipid nanoconstructs against visceral leishmaniasis.
Singodia D; Khare P; Dube A; Talegaonkar S; Khar RK; Mishra PR
J Biomed Nanotechnol; 2011 Feb; 7(1):123-4. PubMed ID: 21485834
[TBL] [Abstract][Full Text] [Related]
12. Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model.
Heidari-Kharaji M; Taheri T; Doroud D; Habibzadeh S; Badirzadeh A; Rafati S
Parasite Immunol; 2016 Oct; 38(10):599-608. PubMed ID: 27213964
[TBL] [Abstract][Full Text] [Related]
13. Nanostructured delivery systems with improved leishmanicidal activity: a critical review.
Bruni N; Stella B; Giraudo L; Della Pepa C; Gastaldi D; Dosio F
Int J Nanomedicine; 2017; 12():5289-5311. PubMed ID: 28794624
[TBL] [Abstract][Full Text] [Related]
14. Antileishmanial dinitroaniline sulfonamides with activity against parasite tubulin.
Bhattacharya G; Salem MM; Werbovetz KA
Bioorg Med Chem Lett; 2002 Sep; 12(17):2395-8. PubMed ID: 12161141
[TBL] [Abstract][Full Text] [Related]
15. In vivo antileishmanial efficacy of a naphthoquinone derivate incorporated into a Pluronic
Mendonça DVC; Tavares GSV; Lage DP; Soyer TG; Carvalho LM; Dias DS; Ribeiro PAF; Ottoni FM; Antinarelli LMR; Vale DL; Ludolf F; Duarte MC; Coimbra ES; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Barichello JM; Alves RJ; Coelho EAF
Biomed Pharmacother; 2019 Jan; 109():779-787. PubMed ID: 30551531
[TBL] [Abstract][Full Text] [Related]
16. Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis.
Azevedo EG; Ribeiro RR; da Silva SM; Ferreira CS; de Souza LE; Ferreira AA; de Oliveira E Castro RA; Demicheli C; Rezende SA; Frézard F
Expert Opin Drug Deliv; 2014 Oct; 11(10):1551-60. PubMed ID: 24962630
[TBL] [Abstract][Full Text] [Related]
17. Sodium stibogluconate loaded nano-deformable liposomes for topical treatment of leishmaniasis: macrophage as a target cell.
Dar MJ; Din FU; Khan GM
Drug Deliv; 2018 Nov; 25(1):1595-1606. PubMed ID: 30105918
[TBL] [Abstract][Full Text] [Related]
18. Development of nanocapsules bearing doxorubicin for macrophage targeting through the phosphatidylserine ligand: a system for intervention in visceral leishmaniasis.
Kansal S; Tandon R; Dwivedi P; Misra P; Verma PR; Dube A; Mishra PR
J Antimicrob Chemother; 2012 Nov; 67(11):2650-60. PubMed ID: 22872448
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic evaluation of free and liposome-loaded furazolidone in experimental visceral leishmaniasis.
Tempone AG; Mortara RA; de Andrade HF; Reimão JQ
Int J Antimicrob Agents; 2010 Aug; 36(2):159-63. PubMed ID: 20554161
[TBL] [Abstract][Full Text] [Related]
20. Formulation and evaluation of oil-in-water emulsions of piperine in visceral leishmaniasis.
Veerareddy PR; Vobalaboina V; Nahid A
Pharmazie; 2004 Mar; 59(3):194-7. PubMed ID: 15074591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
